Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

February 14, 2023

Study Completion Date

June 17, 2024

Conditions
Polycythemia Vera
Interventions
DRUG

PTG-300

Active

DRUG

Placebo

Placebo

Trial Locations (16)

10029

Mount Sinai, New York

10065

New York Presbyterian Hospital - Weill Cornell Medical Center, New York

20817

Center for Cancer and Blood Disorders, Bethesda

33612

Moffitt Cancer Center, Tampa

44106

Cleveland Clinic - Taussig Cancer Center, Cleveland

48109

University of Michigan, Ann Arbor

48201

Karmanos Cancer Center, Detroit

66205

University of Kansas, Westwood

70433

Pontchartrain Cancer Care, Covington

75230

Mary Crowley Cancer Research Center, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

85054

Mayo Clinic - Mayo Clinic Hospital, Phoenix

94304

Stanford University, Palo Alto

94904

Marin Cancer Care, Greenbrae

249203

All India Institute of Medical Sciences, Rishikesh

411004

Sahyadri Super Specialty Hospital, Pune

All Listed Sponsors
lead

Protagonist Therapeutics, Inc.

INDUSTRY

NCT04057040 - Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | Biotech Hunter | Biotech Hunter